GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Accounts Payable

Orphazyme AS (CHIX:ORPHAC) Accounts Payable : kr11.36 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Accounts Payable?

Orphazyme AS's Accounts Payable for the quarter that ended in Jun. 2022 was kr11.36 Mil.

Orphazyme AS's quarterly Accounts Payable declined from Jun. 2021 (kr98.98 Mil) to Dec. 2021 (kr41.78 Mil) and declined from Dec. 2021 (kr41.78 Mil) to Jun. 2022 (kr11.36 Mil).

Orphazyme AS's annual Accounts Payable increased from Dec. 2019 (kr1.09 Mil) to Dec. 2020 (kr29.94 Mil) and increased from Dec. 2020 (kr29.94 Mil) to Dec. 2021 (kr41.78 Mil).

Orphazyme AS Accounts Payable Historical Data

The historical data trend for Orphazyme AS's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Accounts Payable Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Accounts Payable
Get a 7-Day Free Trial 13.44 18.09 1.09 29.94 41.78

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.77 29.94 98.98 41.78 11.36

Orphazyme AS Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Orphazyme AS Accounts Payable Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Accounts Payable
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Website
https://www.orphazyme.com
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines